SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses

BACKGROUND. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 110 million individuals and led to 2.5 million deaths worldwide. As more individuals are vaccinated, the clinical performance and utility of SARS-CoV-2 serology platforms needs to be evaluated. METHODS. Th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:medRxiv
Main Authors: Suhandynata, Raymond T., Bevins, Nicholas J., Tran, Jenny T., Huang, Deli, Hoffman, Melissa A., Lund, Kyle, Kelner, Michael J., McLawhon, Ronald W., Gonias, Steven L., Nemazee, David, Fitzgerald, Robert L.
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7987061/
https://ncbi.nlm.nih.gov/pubmed/33758902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.03.10.21253299
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados